INDICATIONS:Bidoflox is indicated for the treatment of the following bacterial infections if these are due to Ofloxacin-sensitive pathogens.

Acute, chronic or recurrent respiratory tract infections (bronchitis): Caused by Haemophilus influenzae or other gram-negative or multi-drug resistant pathogens, as well as Staphylococcus aureus. Pneumonias, especially if caused by pathogens such as Escherichia coli, Enterobacter, Proteus, Pseudomonas, Legionella or Staphylococcus.

Chronic and recurrent infections of ear, nose and throat: especially if caused by gram-negative pathogens including Pseudomonas or by Staphylococcus (not recommended for treatment of acute tonsillitis).

Skin and skin structure infections: Infections of the abdominal cavity (e.g. bacterial infections of gastrointestinal tract, the biliary duct, peritonitis).

Infections of the kidneys, urinary tract and genital organs: gonorrhoea MDR-TB (Multi-drug resistant tuberculosis)

DOSAGE
The dose of bidoflox is determined by the type and severity of the infection.The dosage range for adults is 200 mg to 800 mg daily. Up to 400 mg as a single dose should be given in the morning. Larger doses should be given as two divided doses.Dosage in patients with impaired liver function: The excretion of bidoflox may be reduced in patients with severe impairment of liver function (e.g. cirrhosis with ascites). A maximum daily dose of 400 mg Ofloxacin should therefore not be exceeded. MDR-TB: bidoflox 400 mg twice daily with first-line anti-TB drugs for 6-9 months. No adjustment of dosage is required in the elderly other than that imposed by consideration of renal function.

CONTRAINDICATIONS
Bidoflox should not be used in patients hypersensitive to ofloxacin or any other quinolone.
Bidoflox is contraindicated in epileptics.
Bidoflox must not be used in patients with pre-existing central nervous system lesions involving a lowered convulsion threshold, e.g. after cerebrocranial injuries, inflammation in the region of the central nervous system or stroke.